Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
Public ClinicalTrials.gov record NCT04454658. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With Myelofibrosis
Study identification
- NCT ID
- NCT04454658
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 21 participants
Conditions and interventions
Conditions
Interventions
- ABBV-744 Drug
- Navitoclax Drug
- Ruxolitinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 10, 2020
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
- Last update posted
- Jul 15, 2025
2020 – 2027
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Davis Comprehensive Cancer Center /ID# 221790 | Sacramento | California | 95817 | — |
| Duplicate_Dartmouth-Hitchcock Medical Center - 1 Medical Center Drive /ID# 224623 | Lebanon | New Hampshire | 03756 | — |
| Roswell Park Cancer Institute /ID# 222557 | Buffalo | New York | 14263 | — |
| The Mount Sinai Hospital /ID# 221549 | New York | New York | 10029 | — |
| Weill Cornell Medical College /ID# 227069 | New York | New York | 10065 | — |
| Gabrail Cancer Center Research /ID# 222802 | Canton | Ohio | 44718 | — |
| University of Oklahoma, Stephenson Cancer Center /ID# 224095 | Oklahoma City | Oklahoma | 73104-5418 | — |
| Oregon Health and Science University /ID# 221801 | Portland | Oregon | 97239 | — |
| Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 240004 | Dallas | Texas | 75246-2003 | — |
| VA Puget Sound Health Care System /ID# 224208 | Seattle | Washington | 98108-1597 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04454658, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 15, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04454658 live on ClinicalTrials.gov.